| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 79 | 2026 | 1192 | 6.990 |
Why?
|
| Transplantation Conditioning | 34 | 2023 | 300 | 3.240 |
Why?
|
| Bone Marrow Transplantation | 64 | 2014 | 618 | 3.060 |
Why?
|
| Graft vs Host Disease | 46 | 2026 | 621 | 2.310 |
Why?
|
| Transplantation, Homologous | 42 | 2026 | 648 | 1.690 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 26 | 2023 | 816 | 1.380 |
Why?
|
| Leukemia | 20 | 2024 | 373 | 1.260 |
Why?
|
| Hematologic Neoplasms | 11 | 2025 | 294 | 1.160 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 4 | 2020 | 35 | 1.090 |
Why?
|
| T-Lymphocytes | 28 | 2024 | 1759 | 1.040 |
Why?
|
| Antibodies, Monoclonal | 14 | 2008 | 1038 | 1.020 |
Why?
|
| Child, Preschool | 101 | 2026 | 14857 | 0.980 |
Why?
|
| Child | 140 | 2026 | 25827 | 0.980 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2019 | 169 | 0.910 |
Why?
|
| Leukemia, Myeloid, Acute | 21 | 2021 | 571 | 0.880 |
Why?
|
| Adolescent | 112 | 2026 | 20553 | 0.880 |
Why?
|
| Immunotherapy, Adoptive | 15 | 2025 | 898 | 0.850 |
Why?
|
| Antibodies, Neoplasm | 6 | 2008 | 59 | 0.790 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.790 |
Why?
|
| Tissue Donors | 12 | 2021 | 508 | 0.770 |
Why?
|
| Infant | 60 | 2026 | 13195 | 0.700 |
Why?
|
| Granulomatous Disease, Chronic | 4 | 2018 | 70 | 0.700 |
Why?
|
| Stem Cell Transplantation | 10 | 2017 | 248 | 0.680 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2018 | 47 | 0.670 |
Why?
|
| Alemtuzumab | 10 | 2023 | 88 | 0.630 |
Why?
|
| Recurrence | 22 | 2023 | 1458 | 0.630 |
Why?
|
| Unrelated Donors | 5 | 2021 | 70 | 0.580 |
Why?
|
| Humans | 194 | 2026 | 132348 | 0.570 |
Why?
|
| Hodgkin Disease | 5 | 2022 | 305 | 0.570 |
Why?
|
| Treatment Outcome | 38 | 2021 | 13017 | 0.550 |
Why?
|
| Male | 117 | 2026 | 65061 | 0.540 |
Why?
|
| T-Lymphocytes, Cytotoxic | 14 | 2014 | 520 | 0.530 |
Why?
|
| Pyridines | 1 | 2018 | 248 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2022 | 1348 | 0.500 |
Why?
|
| Severe Combined Immunodeficiency | 5 | 2021 | 106 | 0.490 |
Why?
|
| Female | 109 | 2026 | 70795 | 0.480 |
Why?
|
| Epstein-Barr Virus Infections | 6 | 2023 | 293 | 0.480 |
Why?
|
| Myeloablative Agonists | 2 | 2015 | 20 | 0.480 |
Why?
|
| Herpesvirus 4, Human | 21 | 2023 | 675 | 0.480 |
Why?
|
| Lymphocyte Transfusion | 4 | 2021 | 58 | 0.470 |
Why?
|
| Autoimmune Diseases | 4 | 2018 | 273 | 0.470 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2021 | 217 | 0.470 |
Why?
|
| Pyrazoles | 1 | 2018 | 330 | 0.470 |
Why?
|
| Antineoplastic Agents | 8 | 2013 | 1829 | 0.470 |
Why?
|
| Salvage Therapy | 4 | 2021 | 201 | 0.460 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 29 | 0.460 |
Why?
|
| Leukocyte Common Antigens | 3 | 2005 | 91 | 0.460 |
Why?
|
| Retrospective Studies | 34 | 2025 | 17364 | 0.450 |
Why?
|
| Young Adult | 23 | 2026 | 9945 | 0.450 |
Why?
|
| Siblings | 3 | 2015 | 202 | 0.440 |
Why?
|
| Whole-Body Irradiation | 13 | 2012 | 60 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 608 | 0.410 |
Why?
|
| Tumor Virus Infections | 6 | 2021 | 140 | 0.400 |
Why?
|
| Cyclophosphamide | 14 | 2023 | 425 | 0.400 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2021 | 127 | 0.400 |
Why?
|
| Living Donors | 4 | 2008 | 116 | 0.390 |
Why?
|
| Virus Diseases | 5 | 2023 | 291 | 0.380 |
Why?
|
| Lymphoproliferative Disorders | 7 | 2015 | 225 | 0.370 |
Why?
|
| Cystitis | 4 | 2021 | 51 | 0.360 |
Why?
|
| Adult | 62 | 2026 | 31619 | 0.360 |
Why?
|
| Anemia, Aplastic | 3 | 2006 | 62 | 0.360 |
Why?
|
| Cytomegalovirus | 7 | 2019 | 263 | 0.350 |
Why?
|
| BK Virus | 3 | 2021 | 60 | 0.340 |
Why?
|
| Immunocompromised Host | 8 | 2015 | 308 | 0.330 |
Why?
|
| Translocation, Genetic | 6 | 2009 | 359 | 0.320 |
Why?
|
| Vidarabine | 2 | 2008 | 80 | 0.310 |
Why?
|
| Caspase 9 | 3 | 2015 | 76 | 0.310 |
Why?
|
| Prospective Studies | 12 | 2026 | 6540 | 0.310 |
Why?
|
| Biomarkers | 7 | 2026 | 3391 | 0.300 |
Why?
|
| Cladribine | 3 | 2001 | 9 | 0.300 |
Why?
|
| Polyomavirus Infections | 2 | 2021 | 91 | 0.300 |
Why?
|
| Hematopoiesis | 3 | 2011 | 225 | 0.290 |
Why?
|
| Neuroblastoma | 9 | 2020 | 550 | 0.290 |
Why?
|
| Immunosuppressive Agents | 8 | 2015 | 672 | 0.290 |
Why?
|
| Donor Selection | 1 | 2008 | 58 | 0.280 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2021 | 36 | 0.280 |
Why?
|
| Survival Analysis | 9 | 2015 | 1570 | 0.280 |
Why?
|
| Genetic Markers | 12 | 1998 | 619 | 0.280 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2019 | 54 | 0.280 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 3 | 2026 | 23 | 0.280 |
Why?
|
| Acute Disease | 17 | 2022 | 1176 | 0.280 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 956 | 0.270 |
Why?
|
| Transplantation, Autologous | 18 | 2022 | 287 | 0.270 |
Why?
|
| Graft Rejection | 3 | 2015 | 560 | 0.270 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2020 | 149 | 0.260 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2005 | 41 | 0.260 |
Why?
|
| Follow-Up Studies | 18 | 2025 | 5405 | 0.260 |
Why?
|
| Antilymphocyte Serum | 6 | 2006 | 42 | 0.260 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 146 | 0.250 |
Why?
|
| Lymphoma | 6 | 2024 | 331 | 0.250 |
Why?
|
| Adoptive Transfer | 3 | 2019 | 241 | 0.250 |
Why?
|
| Burkitt Lymphoma | 3 | 2023 | 141 | 0.240 |
Why?
|
| Survival Rate | 10 | 2020 | 2187 | 0.240 |
Why?
|
| Antigens, CD19 | 2 | 2019 | 182 | 0.240 |
Why?
|
| DNA Viruses | 2 | 2017 | 32 | 0.240 |
Why?
|
| Lymphocyte Depletion | 7 | 2024 | 125 | 0.230 |
Why?
|
| Leukemia, Myeloid | 10 | 2006 | 81 | 0.230 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2023 | 150 | 0.230 |
Why?
|
| Herpesviridae Infections | 7 | 2013 | 146 | 0.230 |
Why?
|
| Busulfan | 2 | 2023 | 43 | 0.230 |
Why?
|
| Infant, Newborn | 14 | 2020 | 8568 | 0.230 |
Why?
|
| Interleukin-2 | 4 | 2014 | 241 | 0.220 |
Why?
|
| Guillain-Barre Syndrome | 2 | 2018 | 31 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 2 | 2019 | 148 | 0.210 |
Why?
|
| Cell Phone | 2 | 2014 | 36 | 0.210 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 30 | 0.210 |
Why?
|
| Remission Induction | 13 | 2017 | 307 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 667 | 0.210 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2023 | 14 | 0.200 |
Why?
|
| Cytarabine | 12 | 2022 | 102 | 0.200 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2003 | 266 | 0.200 |
Why?
|
| Complement Activation | 1 | 2003 | 49 | 0.200 |
Why?
|
| Antiviral Agents | 3 | 2023 | 822 | 0.200 |
Why?
|
| Transplant Recipients | 3 | 2020 | 225 | 0.200 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 52 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2008 | 558 | 0.190 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2014 | 210 | 0.180 |
Why?
|
| Adenosine Deaminase | 2 | 2021 | 89 | 0.180 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 245 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 165 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 44 | 0.180 |
Why?
|
| Leukemia, Lymphoid | 7 | 1999 | 104 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 103 | 0.170 |
Why?
|
| Thiotepa | 2 | 2020 | 14 | 0.170 |
Why?
|
| Triazoles | 2 | 2011 | 147 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 2 | 2021 | 344 | 0.170 |
Why?
|
| Prognosis | 12 | 2025 | 5010 | 0.160 |
Why?
|
| Antifungal Agents | 3 | 2011 | 312 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 295 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2000 | 102 | 0.160 |
Why?
|
| Neoplasms | 8 | 2025 | 2946 | 0.160 |
Why?
|
| Graft Survival | 4 | 2015 | 475 | 0.150 |
Why?
|
| Chronic Disease | 4 | 2026 | 1229 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 55 | 0.150 |
Why?
|
| Leukemia, Promyelocytic, Acute | 3 | 2004 | 23 | 0.150 |
Why?
|
| Thrombocytopenia | 3 | 2024 | 234 | 0.150 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.150 |
Why?
|
| Methotrexate | 9 | 2015 | 351 | 0.150 |
Why?
|
| Infection Control | 2 | 2018 | 158 | 0.150 |
Why?
|
| Epitopes | 2 | 2015 | 437 | 0.150 |
Why?
|
| Adenoviridae | 6 | 2019 | 596 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2011 | 419 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 499 | 0.140 |
Why?
|
| Combined Modality Therapy | 13 | 2021 | 1297 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2014 | 761 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 1303 | 0.140 |
Why?
|
| Organophosphonates | 1 | 2018 | 21 | 0.140 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 74 | 0.140 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 129 | 0.140 |
Why?
|
| Cytosine | 1 | 2018 | 59 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Hepatic Artery | 1 | 1997 | 47 | 0.140 |
Why?
|
| Risk Factors | 14 | 2026 | 10911 | 0.140 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Adenoviridae Infections | 2 | 2013 | 69 | 0.140 |
Why?
|
| Plasma Exchange | 1 | 2018 | 88 | 0.140 |
Why?
|
| Histiocytes | 1 | 2017 | 25 | 0.140 |
Why?
|
| Bone Marrow Purging | 7 | 2003 | 34 | 0.140 |
Why?
|
| Adenovirus Infections, Human | 2 | 2009 | 57 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 172 | 0.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2015 | 241 | 0.130 |
Why?
|
| Cranial Irradiation | 2 | 2008 | 72 | 0.130 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2017 | 34 | 0.130 |
Why?
|
| Oncogene Proteins | 2 | 1997 | 144 | 0.130 |
Why?
|
| Histocompatibility | 3 | 2006 | 42 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 109 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 1997 | 194 | 0.130 |
Why?
|
| Nurse's Role | 2 | 2014 | 41 | 0.130 |
Why?
|
| Infusions, Intravenous | 7 | 2011 | 558 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 328 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 1997 | 137 | 0.130 |
Why?
|
| Ricin | 2 | 1994 | 12 | 0.130 |
Why?
|
| Immunotoxins | 2 | 1994 | 21 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1997 | 109 | 0.130 |
Why?
|
| Retinal Diseases | 1 | 2019 | 179 | 0.130 |
Why?
|
| Methylprednisolone | 2 | 1995 | 97 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1997 | 142 | 0.120 |
Why?
|
| Osteosarcoma | 2 | 2015 | 263 | 0.120 |
Why?
|
| Gene Transfer Techniques | 8 | 2011 | 350 | 0.120 |
Why?
|
| Lymph Nodes | 3 | 2017 | 388 | 0.120 |
Why?
|
| Age Factors | 7 | 2026 | 2931 | 0.120 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 48 | 0.120 |
Why?
|
| Cardiac Tamponade | 1 | 1995 | 38 | 0.120 |
Why?
|
| Diarrhea | 2 | 2015 | 333 | 0.120 |
Why?
|
| Incidence | 7 | 2018 | 3362 | 0.120 |
Why?
|
| Leukocyte Count | 6 | 1996 | 249 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 536 | 0.120 |
Why?
|
| Portal Vein | 1 | 1995 | 91 | 0.120 |
Why?
|
| Antigens, CD | 4 | 2005 | 437 | 0.120 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2008 | 56 | 0.110 |
Why?
|
| B-Lymphocytes | 4 | 2013 | 543 | 0.110 |
Why?
|
| Brain Neoplasms | 4 | 2008 | 1409 | 0.110 |
Why?
|
| Lung Diseases | 2 | 1996 | 409 | 0.110 |
Why?
|
| Receptors, Fc | 1 | 2014 | 33 | 0.110 |
Why?
|
| Mucolipidoses | 1 | 2014 | 7 | 0.110 |
Why?
|
| Phosphoglucomutase | 1 | 2014 | 7 | 0.110 |
Why?
|
| Neutropenia | 3 | 2024 | 205 | 0.110 |
Why?
|
| Thrombopoietin | 1 | 2014 | 33 | 0.110 |
Why?
|
| Immune System | 1 | 2015 | 97 | 0.110 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 445 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 1996 | 372 | 0.110 |
Why?
|
| Podophyllotoxin | 2 | 1999 | 7 | 0.110 |
Why?
|
| Immunophenotyping | 9 | 2014 | 344 | 0.110 |
Why?
|
| Allografts | 3 | 2021 | 196 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2015 | 174 | 0.110 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 60 | 0.110 |
Why?
|
| Bone Diseases, Developmental | 1 | 2014 | 60 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 3 | 2019 | 225 | 0.110 |
Why?
|
| Albumins | 1 | 2014 | 96 | 0.110 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2014 | 45 | 0.100 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 17 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1126 | 0.100 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 403 | 0.100 |
Why?
|
| Micrococcaceae | 1 | 2013 | 5 | 0.100 |
Why?
|
| Liver Diseases | 1 | 1997 | 387 | 0.100 |
Why?
|
| Tretinoin | 1 | 1993 | 102 | 0.100 |
Why?
|
| Tacrolimus | 2 | 2006 | 104 | 0.100 |
Why?
|
| Risk | 2 | 2015 | 763 | 0.100 |
Why?
|
| Actinomycetales Infections | 1 | 2013 | 15 | 0.100 |
Why?
|
| Dyskeratosis Congenita | 1 | 2013 | 19 | 0.100 |
Why?
|
| Middle Aged | 17 | 2024 | 28891 | 0.100 |
Why?
|
| Viruses | 1 | 2014 | 126 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 336 | 0.100 |
Why?
|
| Neomycin | 5 | 2000 | 36 | 0.100 |
Why?
|
| Bone Marrow Cells | 5 | 2005 | 263 | 0.100 |
Why?
|
| Proteome | 1 | 2014 | 278 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 947 | 0.100 |
Why?
|
| Pseudotumor Cerebri | 1 | 1993 | 66 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 198 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2015 | 181 | 0.100 |
Why?
|
| Karyotyping | 6 | 2009 | 319 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2062 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 175 | 0.090 |
Why?
|
| Sibling Relations | 1 | 2011 | 12 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2012 | 78 | 0.090 |
Why?
|
| Mutation | 2 | 2017 | 6248 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2014 | 199 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 234 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1992 | 94 | 0.090 |
Why?
|
| Self Care | 1 | 2013 | 227 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1683 | 0.090 |
Why?
|
| Caliciviridae Infections | 1 | 2015 | 360 | 0.090 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 43 | 0.090 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 72 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 7 | 1996 | 554 | 0.090 |
Why?
|
| Retroviridae | 5 | 2019 | 194 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1098 | 0.090 |
Why?
|
| Genome, Human | 1 | 2018 | 1332 | 0.090 |
Why?
|
| Norovirus | 1 | 2015 | 349 | 0.090 |
Why?
|
| Bone Marrow | 7 | 2018 | 332 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 1153 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 1997 | 2687 | 0.080 |
Why?
|
| Aziridines | 1 | 1990 | 11 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 1247 | 0.080 |
Why?
|
| Proteomics | 1 | 2014 | 594 | 0.080 |
Why?
|
| Benzoquinones | 1 | 1990 | 19 | 0.080 |
Why?
|
| Educational Status | 1 | 2011 | 295 | 0.080 |
Why?
|
| Aspergillosis | 2 | 2014 | 46 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2009 | 2494 | 0.080 |
Why?
|
| Philadelphia Chromosome | 2 | 2008 | 43 | 0.080 |
Why?
|
| Pilot Projects | 6 | 2020 | 1454 | 0.080 |
Why?
|
| Organic Chemicals | 3 | 2015 | 59 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 803 | 0.080 |
Why?
|
| Liver Function Tests | 3 | 2011 | 104 | 0.080 |
Why?
|
| Texas | 4 | 2021 | 3629 | 0.080 |
Why?
|
| Cisplatin | 4 | 2015 | 281 | 0.080 |
Why?
|
| Melphalan | 2 | 2022 | 46 | 0.080 |
Why?
|
| Peroxidase | 1 | 2009 | 64 | 0.080 |
Why?
|
| Medulloblastoma | 2 | 2006 | 571 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 428 | 0.080 |
Why?
|
| Aged | 8 | 2024 | 21381 | 0.080 |
Why?
|
| Kinetics | 1 | 2011 | 1179 | 0.070 |
Why?
|
| National Health Programs | 1 | 2008 | 20 | 0.070 |
Why?
|
| Rotavirus Infections | 1 | 2011 | 359 | 0.070 |
Why?
|
| Supratentorial Neoplasms | 1 | 2008 | 40 | 0.070 |
Why?
|
| Hospitals | 2 | 2021 | 436 | 0.070 |
Why?
|
| Genetic Vectors | 5 | 2019 | 927 | 0.070 |
Why?
|
| Chromosome Aberrations | 4 | 2018 | 591 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 1672 | 0.070 |
Why?
|
| Multiple Sclerosis | 3 | 2004 | 382 | 0.070 |
Why?
|
| Cell Division | 4 | 2004 | 744 | 0.070 |
Why?
|
| Drug Administration Schedule | 6 | 2011 | 748 | 0.070 |
Why?
|
| Teniposide | 1 | 1987 | 2 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 56 | 0.070 |
Why?
|
| Lymphocytes | 3 | 2006 | 365 | 0.070 |
Why?
|
| Feasibility Studies | 5 | 2014 | 826 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 557 | 0.070 |
Why?
|
| Immunoglobulin G | 3 | 2018 | 803 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2006 | 108 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 139 | 0.070 |
Why?
|
| Haplotypes | 3 | 2015 | 545 | 0.060 |
Why?
|
| Myelin Basic Protein | 2 | 2004 | 67 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2022 | 566 | 0.060 |
Why?
|
| Lymphocyte Count | 3 | 2014 | 120 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2006 | 127 | 0.060 |
Why?
|
| Cells, Cultured | 6 | 2017 | 3062 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2006 | 52 | 0.060 |
Why?
|
| Prednisone | 6 | 2014 | 252 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2018 | 5150 | 0.060 |
Why?
|
| Virus Activation | 4 | 2005 | 85 | 0.060 |
Why?
|
| Comorbidity | 1 | 2011 | 1605 | 0.060 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2005 | 36 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2005 | 64 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2000 | 720 | 0.060 |
Why?
|
| HLA Antigens | 2 | 2019 | 220 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 69 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 288 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2006 | 449 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2006 | 503 | 0.060 |
Why?
|
| Flow Cytometry | 4 | 2015 | 806 | 0.060 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2004 | 7 | 0.060 |
Why?
|
| Etoposide | 4 | 2014 | 120 | 0.060 |
Why?
|
| Syndactyly | 1 | 2005 | 24 | 0.060 |
Why?
|
| Laryngeal Diseases | 1 | 2004 | 32 | 0.060 |
Why?
|
| United States | 5 | 2013 | 11628 | 0.060 |
Why?
|
| Laryngectomy | 1 | 2004 | 32 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2005 | 76 | 0.060 |
Why?
|
| Quality of Life | 2 | 2011 | 2151 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 44 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 1995 | 31 | 0.050 |
Why?
|
| Antigens, Differentiation | 2 | 1995 | 67 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 188 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1994 | 79 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2004 | 85 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2003 | 22 | 0.050 |
Why?
|
| Adenoviruses, Human | 2 | 2017 | 97 | 0.050 |
Why?
|
| Cytokines | 3 | 2021 | 1368 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2004 | 2169 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2015 | 303 | 0.050 |
Why?
|
| Rituximab | 2 | 2022 | 166 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 109 | 0.050 |
Why?
|
| Abscess | 1 | 2004 | 140 | 0.050 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 14 | 0.050 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 1993 | 19 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2005 | 461 | 0.050 |
Why?
|
| Hematologic Diseases | 4 | 2014 | 82 | 0.050 |
Why?
|
| DNA, Viral | 5 | 2009 | 492 | 0.050 |
Why?
|
| Agranulocytosis | 1 | 1982 | 13 | 0.050 |
Why?
|
| Myositis Ossificans | 1 | 1983 | 8 | 0.050 |
Why?
|
| Cell Line | 5 | 2013 | 2730 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 174 | 0.050 |
Why?
|
| Time Factors | 8 | 2014 | 6456 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 377 | 0.050 |
Why?
|
| Periodicity | 1 | 1982 | 51 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 471 | 0.050 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 2002 | 4 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2011 | 704 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2003 | 118 | 0.050 |
Why?
|
| Leukemia, T-Cell | 1 | 2002 | 11 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2006 | 461 | 0.050 |
Why?
|
| Respirovirus Infections | 1 | 2002 | 20 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 6 | 2009 | 1556 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2014 | 748 | 0.050 |
Why?
|
| Voriconazole | 2 | 2011 | 34 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2011 | 26 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 40 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2005 | 657 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 63 | 0.040 |
Why?
|
| Postoperative Complications | 4 | 2014 | 3139 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 56 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2021 | 114 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2002 | 377 | 0.040 |
Why?
|
| Chemokines, C | 1 | 2000 | 10 | 0.040 |
Why?
|
| Histocompatibility Testing | 3 | 2009 | 111 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 44 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2001 | 187 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 66 | 0.040 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 14 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2019 | 30 | 0.040 |
Why?
|
| Gene Expression | 2 | 2014 | 1564 | 0.040 |
Why?
|
| Drug Evaluation | 5 | 1990 | 104 | 0.040 |
Why?
|
| Viral Load | 2 | 2016 | 410 | 0.040 |
Why?
|
| Vincristine | 4 | 2008 | 195 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1132 | 0.040 |
Why?
|
| Biopsy | 3 | 2018 | 1289 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 33 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1451 | 0.040 |
Why?
|
| Antigens, Viral | 2 | 2013 | 439 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 41 | 0.040 |
Why?
|
| Blast Crisis | 2 | 1994 | 17 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 303 | 0.030 |
Why?
|
| Data Collection | 2 | 2014 | 389 | 0.030 |
Why?
|
| XYY Karyotype | 1 | 1997 | 2 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 1443 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2002 | 804 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 55 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 87 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2014 | 338 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 167 | 0.030 |
Why?
|
| Animals | 7 | 2013 | 34995 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 273 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 1997 | 186 | 0.030 |
Why?
|
| Rats | 1 | 2003 | 3620 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2014 | 2512 | 0.030 |
Why?
|
| Immunologic Memory | 2 | 2009 | 199 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1996 | 77 | 0.030 |
Why?
|
| Chimera | 1 | 1996 | 84 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 1997 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2011 | 247 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1996 | 87 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 32 | 0.030 |
Why?
|
| Drug Resistance | 4 | 2001 | 252 | 0.030 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 8 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 1995 | 21 | 0.030 |
Why?
|
| Membrane Lipids | 1 | 1995 | 31 | 0.030 |
Why?
|
| Glycolipids | 1 | 1995 | 33 | 0.030 |
Why?
|
| Pedigree | 2 | 2014 | 1725 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1996 | 148 | 0.030 |
Why?
|
| Anorexia | 1 | 1995 | 22 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 816 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 2706 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 231 | 0.030 |
Why?
|
| Brain | 2 | 2004 | 3198 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1998 | 214 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1997 | 234 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 7 | 0.030 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 216 | 0.030 |
Why?
|
| Hemorrhage | 2 | 1999 | 517 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 144 | 0.030 |
Why?
|
| Mycoplasma Infections | 1 | 1994 | 10 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 85 | 0.030 |
Why?
|
| Mesna | 1 | 1994 | 7 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 399 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 97 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 47 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1994 | 58 | 0.030 |
Why?
|
| Pediatric Nursing | 1 | 2014 | 25 | 0.030 |
Why?
|
| Stem Cells | 2 | 2014 | 732 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 443 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 77 | 0.030 |
Why?
|
| Killer Cells, Natural | 2 | 1995 | 351 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 134 | 0.030 |
Why?
|
| Bone Diseases | 1 | 1994 | 46 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 1995 | 149 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 170 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 38 | 0.030 |
Why?
|
| Mice | 4 | 2013 | 18572 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 65 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 544 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1995 | 269 | 0.030 |
Why?
|
| Aging | 1 | 2000 | 1261 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 111 | 0.020 |
Why?
|
| Phenotype | 2 | 2017 | 4545 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 544 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1992 | 70 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 91 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1992 | 42 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2013 | 159 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1992 | 82 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1994 | 158 | 0.020 |
Why?
|
| Cyclosporins | 3 | 1987 | 15 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1996 | 615 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2012 | 5 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 2145 | 0.020 |
Why?
|
| Leukocytes | 1 | 1993 | 210 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 1992 | 2 | 0.020 |
Why?
|
| Neprilysin | 1 | 1992 | 21 | 0.020 |
Why?
|
| Sex Factors | 1 | 1996 | 1353 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 37 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 381 | 0.020 |
Why?
|
| Gentamicins | 1 | 1992 | 87 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1996 | 701 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1994 | 173 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1992 | 111 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 303 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 795 | 0.020 |
Why?
|
| Wilms Tumor | 1 | 1992 | 119 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 421 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 1994 | 295 | 0.020 |
Why?
|
| Feces | 1 | 2015 | 780 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 3 | 1998 | 197 | 0.020 |
Why?
|
| Life Tables | 2 | 1997 | 27 | 0.020 |
Why?
|
| Syndrome | 1 | 1993 | 1171 | 0.020 |
Why?
|
| Platelet Count | 1 | 1991 | 141 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1993 | 215 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1831 | 0.020 |
Why?
|
| Sarcoma | 1 | 1992 | 208 | 0.020 |
Why?
|
| Transfection | 1 | 1992 | 999 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1996 | 1285 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 1006 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 483 | 0.020 |
Why?
|
| Echocardiography | 1 | 1995 | 1125 | 0.020 |
Why?
|
| Kanamycin Kinase | 3 | 1994 | 16 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 1998 | 4695 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 133 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1991 | 123 | 0.020 |
Why?
|
| Clinical Protocols | 3 | 1996 | 241 | 0.020 |
Why?
|
| Safety | 3 | 1994 | 217 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2009 | 158 | 0.020 |
Why?
|
| Isoantibodies | 2 | 1986 | 59 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 219 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2009 | 122 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 105 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 68 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2008 | 42 | 0.020 |
Why?
|
| Glioma | 1 | 1993 | 534 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2005 | 1098 | 0.020 |
Why?
|
| Fever | 1 | 1991 | 312 | 0.020 |
Why?
|
| Mercaptopurine | 3 | 1995 | 72 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 1707 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 775 | 0.020 |
Why?
|
| Pneumonia | 1 | 1991 | 336 | 0.020 |
Why?
|
| Daunorubicin | 3 | 1995 | 27 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 825 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 802 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 2 | 1994 | 348 | 0.020 |
Why?
|
| Base Sequence | 3 | 1996 | 2904 | 0.020 |
Why?
|
| Myeloproliferative Disorders | 1 | 1987 | 91 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2557 | 0.020 |
Why?
|
| Anthraquinones | 1 | 1986 | 9 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 53 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1046 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1996 | 3780 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2005 | 7 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 76 | 0.010 |
Why?
|
| Hemolysis | 1 | 1986 | 116 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3873 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 1294 | 0.010 |
Why?
|
| Zinc Finger Protein Gli3 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Registries | 1 | 2012 | 1585 | 0.010 |
Why?
|
| Length of Stay | 1 | 1991 | 1378 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1986 | 222 | 0.010 |
Why?
|
| Ikaros Transcription Factor | 1 | 2005 | 32 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4725 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1904 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 433 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 3980 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 51 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 120 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 4767 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 100 | 0.010 |
Why?
|
| Asparaginase | 2 | 1995 | 49 | 0.010 |
Why?
|
| Brazil | 1 | 1993 | 138 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1995 | 234 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 188 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 61 | 0.010 |
Why?
|
| Dogs | 1 | 1982 | 655 | 0.010 |
Why?
|
| Horses | 1 | 2001 | 104 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 539 | 0.010 |
Why?
|
| Topotecan | 1 | 2001 | 49 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 2064 | 0.010 |
Why?
|
| Informed Consent | 2 | 1994 | 346 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1292 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 258 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 688 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 879 | 0.010 |
Why?
|
| Pediatrics | 1 | 1990 | 1215 | 0.010 |
Why?
|
| Leukemia L1210 | 1 | 1980 | 5 | 0.010 |
Why?
|
| Down Syndrome | 1 | 1993 | 230 | 0.010 |
Why?
|
| Family | 1 | 2003 | 595 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2001 | 165 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 329 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 40 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 2228 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 63 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2002 | 392 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 519 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2000 | 294 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2001 | 295 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 1047 | 0.010 |
Why?
|
| Central Nervous System Diseases | 2 | 1994 | 109 | 0.010 |
Why?
|
| Liver Failure | 1 | 1999 | 91 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1998 | 181 | 0.010 |
Why?
|
| Cell Survival | 2 | 1996 | 869 | 0.010 |
Why?
|
| S Phase | 1 | 1997 | 76 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1980 | 325 | 0.010 |
Why?
|
| Lung | 3 | 1994 | 1555 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1997 | 95 | 0.010 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1996 | 18 | 0.010 |
Why?
|
| Genes, abl | 1 | 1996 | 7 | 0.010 |
Why?
|
| Chromosome Inversion | 1 | 1997 | 77 | 0.010 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 1996 | 13 | 0.010 |
Why?
|
| Global Health | 1 | 2001 | 619 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 1996 | 10 | 0.010 |
Why?
|
| Cell Count | 1 | 1997 | 234 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 90 | 0.010 |
Why?
|
| Arm | 1 | 1996 | 81 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 51 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1996 | 109 | 0.010 |
Why?
|
| Leg | 1 | 1996 | 134 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 1999 | 366 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 1995 | 45 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1980 | 410 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 637 | 0.010 |
Why?
|
| Introns | 1 | 1996 | 304 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1995 | 79 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 215 | 0.010 |
Why?
|
| Gastrostomy | 1 | 1995 | 92 | 0.010 |
Why?
|
| Mycoses | 1 | 1996 | 117 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 98 | 0.010 |
Why?
|
| Leukemic Infiltration | 1 | 1994 | 8 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 108 | 0.010 |
Why?
|
| Mycoplasma | 1 | 1994 | 4 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 1305 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1994 | 37 | 0.010 |
Why?
|
| Osteochondroma | 1 | 1994 | 5 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 41 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1994 | 18 | 0.010 |
Why?
|
| Pharynx | 1 | 1994 | 67 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1994 | 33 | 0.010 |
Why?
|
| Self Concept | 1 | 1995 | 164 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1994 | 149 | 0.010 |
Why?
|
| Forecasting | 1 | 1995 | 373 | 0.010 |
Why?
|
| Clone Cells | 1 | 1994 | 179 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1357 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1994 | 81 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1987 | 1163 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 803 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1994 | 383 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 227 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1996 | 493 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 1999 | 390 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1995 | 686 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1993 | 99 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 604 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1993 | 240 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1992 | 140 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 324 | 0.010 |
Why?
|
| Skin | 2 | 1986 | 540 | 0.010 |
Why?
|
| Survivors | 1 | 1995 | 359 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 184 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1996 | 1368 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1993 | 145 | 0.010 |
Why?
|
| Brachytherapy | 1 | 1993 | 95 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1992 | 69 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 1992 | 40 | 0.010 |
Why?
|
| Amsacrine | 1 | 1992 | 5 | 0.010 |
Why?
|
| 2-Chloroadenosine | 1 | 1992 | 5 | 0.010 |
Why?
|
| Cause of Death | 1 | 1994 | 503 | 0.010 |
Why?
|
| Deoxyadenosines | 1 | 1992 | 9 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1993 | 127 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 2673 | 0.010 |
Why?
|
| Azacitidine | 1 | 1992 | 53 | 0.010 |
Why?
|
| Radiography | 1 | 1994 | 818 | 0.010 |
Why?
|
| Probability | 1 | 1992 | 323 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1426 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 989 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 1964 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1992 | 235 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1992 | 312 | 0.010 |
Why?
|
| Leucovorin | 1 | 1990 | 54 | 0.000 |
Why?
|
| Cognition | 1 | 1995 | 814 | 0.000 |
Why?
|
| Research Design | 1 | 1994 | 750 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 296 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1988 | 237 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1987 | 137 | 0.000 |
Why?
|
| Random Allocation | 1 | 1987 | 431 | 0.000 |
Why?
|
| Peritoneum | 1 | 1986 | 39 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1986 | 27 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1986 | 250 | 0.000 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1986 | 12 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1986 | 118 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1986 | 94 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1985 | 6 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1988 | 370 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1986 | 66 | 0.000 |
Why?
|
| Spleen | 1 | 1986 | 275 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1986 | 274 | 0.000 |
Why?
|
| Antibodies | 1 | 1985 | 368 | 0.000 |
Why?
|
| Patient Isolation | 1 | 1983 | 15 | 0.000 |
Why?
|
| Cardiomyopathies | 1 | 1986 | 508 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1980 | 52 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1980 | 102 | 0.000 |
Why?
|
| Megakaryocytes | 1 | 1980 | 44 | 0.000 |
Why?
|
| Demyelinating Diseases | 1 | 1980 | 70 | 0.000 |
Why?
|